Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Health

>> CERVICAL CANCER Latest News

FEB 08, 2013 - Health Canal

A Must Read - Share

Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer

Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial.

Tags: Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer,  Cervical Cancer Latest News